Funder: Eli Lilly and Company
Due Dates (Anticipated): May 2026 (Letter of Intent) | June 2026 (Full Application)
Funding Amounts: Funding level and duration vary by RFP; typically supports full study costs, including drug supply if applicable.
Summary: Supports investigator-initiated clinical research aligned with Lilly's therapeutic interests, with proposals reviewed by internal and external experts.